Pediatric rheumatologists,researchers and families, working hand in hand to support groundbreaking, life-changing research and treatment for children living with arthritis and lupus.
View more


2nd Annual - Dickens Holiday Pageant 2018

Dickens Holiday Pageant 2017

Dicken’s Holiday Pageant at Harbor UCLA Hospital

Thank you to Harbor-UCLA Medical Center for hosting the winter holiday event and bringing joy to these wonderful families.
Lupus Foundation of America Breaking News: Inside Lupus Research Dear Friend, Today, AstraZeneca announced that the Phase III TULIP 2 trial for anifrolumab, a potential new medicine for treatment in adults with moderate-to-severe lupus, met its primary endpoint of achieving a reduction in disease activity versus the placebo. Susan Manzi, MD, MPH, Lupus Foundation of America board chair, co-director of the Lupus Center of Excellence and chair of the Department of Medicine of West Penn Allegheny Health System in Pittsburgh said, “The positive trial results released today are encouraging as the top line data suggests anifrolumab achieved clinically significant disease activity reductions across multiple organ systems. Lupus can affect any organ system in the body and people with the disease frequently have multiple organs involved. The news today provides hope that another therapy may soon be added to the many treatments required to manage this devastating and potentially fatal autoimmune disease.” The TULIP 2 trial involved administering a 300mg dose of anifrolumab or placebo, whereas the TULIP 1 trial, which reported results a year ago, had groups of patients receiving 150mg, 300mg or placebo. The TULIP 1 trial did not meet its primary endpoints. TULIP 2 also employed a different assessment tool, which measured results across all organ systems. Mene Pangalos, Executive Vice President, BioPharmaceuticals R&D for AstraZeneca, in the company announcement noted that: “Systemic lupus erythematosus is a debilitating autoimmune disease, but only one new treatment has been approved in the last 60 years. These are important results and we will now review the full data set and explore pathways to bring this potential new treatment to patients.” For the full announcement from AstraZeneca, click here.

Groundbreaking Pediatric Research

The Pediatric Arthritis & Lupus (PAL) Foundation is a non-profit organization that supports innovative pediatric rheumatology research in Southern California to find more effective treatments and solutions for the 385,000 children with pediatric arthritis and lupus. The children and families who suffer from these devastating illnesses are counting on the help of bighearted individuals and organizations who believe in creating change by pioneering groundbreaking research.

You can be one of them.

Your generosity can make a real difference in a child’s health, happiness and well-being.

All research will be made available to the public and those with an interest in pediatric lupus and arthritis.

Our Mission

Nothing is more painful than to see young people afflicted with a debilitating illness. Pediatric arthritis and lupus, as well as the potent medications necessary in treatment, are debilitating and occasionally life-threatening in lupus patients. The mission of the Pediatric Arthritis and Lupus (PAL) Foundation is to advance research and enhance the quality of life for the children who suffer from the disease.

The aim of research is twofold:

• First, to discover greater understanding of the origin, development and treatment of pediatric lupus and rheumatoid disease;

• Second, to develop new and better means of aiding patients with quality of life issues.

The PAL Foundation is committed to encouraging and supporting young researchers dedicated to the Foundation’s mission and to providing resources that will enable them to become the next academic leaders in Pediatric Rheumatology.

View more

We can’t do it without your help..... Donate Now